Arrowhead Pharmaceuticals, Inc.
Compositions and methods for inhibiting gene expression of hepatitis B virus

Last updated:

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.

Status:
Grant
Type:

Utility

Filling date:

19 Aug 2016

Issue date:

8 Dec 2020